Meloxicam - preferred non-steroid anti-inflammatory cyclooxygenase-2 inhibitor


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Non-steroidal anti-inflammatory drugs (NSAIDs) are the most widely used treatment for acute and chronic pain syndromes. However, their use may be accompanied by the development of dangerous complications in the form of organic and functional disorders of the cardiovascular system and the gastrointestinal tract. Currently, wide range of NSAIDs is available, but none of the representatives of this group of drugs can be considered the best. The most acceptable choice for most patients in this situation is a moderately selective NSAID, such as meloxicam. This drug has been widely used in clinical practice worldwide for a long time and has earned the trust of doctors and patients. The main advantages of meloxicam are proven efficacy, convenient regimen of use, a relatively low risk of compli- cations in the form of organic and functional disorders of the cardiovascular system and the gastrointestinal tract, as well as good com- patibility with low doses of acetylsalicylic acid. The authors conducted a study on the pharmaceutical equivalence of various meloxicams existing on the domestic market, and obtained interesting data presented in this article

Full Text

Restricted Access

About the authors

E. Yu Plotnikova

Kemerovo State Medical University

Email: eka-pl@rambler.ru
Dr. Sci. (Med.), Professor of the Department of Outpatient Therapy, Postgraduate Education and Nursing Care, Head of the Course of Clinical Gastroenterology 22a, Voroshilov str., Kemerovo 650022, Russian Federation

M. N Sinkova

Kemerovo State Medical University

Kemerovo, Russia

L. K Isakov

Kemerovo State Medical University

Kemerovo, Russia

A. S Sukhikh

Kemerovo State Medical University

Kemerovo, Russia

References

  1. Vane J.R. Inhibition of prostaglandin synthesis as a mechanism of action for Aspirin-like drugs. Nat New Biol. 1971;231:232-35. Doi: 10.1038/ newbio231232a0.
  2. FitzGerald G.A., Patrono C. The coxibs, selective inhibitors of cyclooxygenase 2. NEJM. 2001;345:433-42. Doi: 10.1056/ NEJM200108093450607.
  3. Davies N.M., Skjodt N.M. Clinical pharmacokinetics of meloxicam. A cyclo-oxygenase-2 preferential nonsteroidal anti-inflammatory drug. Clin Pharmacokinet. 1999;36:115-26. doi: 10.2165/00003088-199936020-00003.
  4. Turck D., Busch U., Heinzel G., Narjes H. Clinical pharmacokinetics of meloxicam. Arzneimittelforschung. 1997;47(3):253-58.
  5. Combe B, Velicitat P, Garzon N., Bluhmki E. Comparison of intramuscular and oral meloxicam in rheumatoid arthritis patients. Inflamm Res. 2001;50(Suppl. 1):S10-6. Doi: 10.1007/ PL00022374.
  6. Gates B.J., Nguyen T.T., Setter S.M., Davies N.M. Meloxicam: a reappraisal of pharmacokinetics, efficacy and safety. Exp Opin Pharmacother 2005;6(12):2117-40. doi: 10.1517/14656566.6.12.2117.
  7. Euller-Ziegler L., Velicitat P, Bluhmki E., et al. Meloxicam: a review of its pharmacokinetics, efficacy and tolerability following intramuscular administration. Inflamm Res. 2001;50(Suppl. 1):S5-9. doi: 10.1007/PL00022377.
  8. Gschwend M.H., Erenmemisoglu A., Martin W., et al. Pharmacokinetic and bioequivalence study of meloxicam tablets in healthy male subjects. Arzneimittelforschung. 2007;57(5):264-68. doi: 10.1055/s-0031-1296616.
  9. Degner F, Sigmund R., Zeidler H. Efficacy and tolerability of meloxicam in an observational, controlled cohort study in patients with rheumatic disease. Clin Ther. 2000;22:400-10. doi: 10.1016/S0149-2918(00)89009-8.
  10. Deeks J.J., Smith L.A., Bradley M.D. Efficacy, tolerability, and upper gastrointestinal safety of celecoxib for treatment of osteoarthritis and rheumatoid arthritis: systematic review of randomised controlled trials. BMJ. 2002;325(7365):619. Doi: 10.1136/ bmj.325.7365.619.
  11. Kirchgessner M.S. Meloxicam. J. Exotic Pet. Med. 2006;15(4):281-83. Doi: 10.1053/j. jepm.2006.09.009.
  12. Pairet M., van Ryn J., Schierok H., et al. Differential inhibition of cyclooxygenases-1 and -2 by meloxicam and its 4'-isomer. Inflamm. Res. 1998;47(6):270-76. Doi: 10.1007/ s000110050329.
  13. Senna G.E., Passalacqua G., Dama A., et al. Nimesulide and meloxicam are a safe alternative drugs for patients intolerant to nonsteroidal antiinflammatory drugs. Eur Ann Allergy Clin Immunol. 2003;35(10):393-96.
  14. Imbimbo B.P, Solfrizzi V., Panza F. Are NSAIDs useful to treat Alzheimer's disease or mild cognitive impairment? Front. Aging Neurosci. 2010;2:19. doi: 10.3389/fnagi.2010.00019.
  15. Goldman A.P, Williams C.S., Sheng H., et al. Meloxicam inhibits the growth of colorectal cancer cells. Carcinogenesis. 1998;19(12):2195-99. doi: 10.1093/carcin/19.12.2195.
  16. Tsubouchi Y, Mukai S., Kawahito Y, et al. Meloxicam inhibits the growth of non-small cell lung cancer. Anticancer Res. 1999;20(5A): 2867-72.
  17. Montejo C., Barcia E., Negro S., et al. Effective antiproliferative effect of meloxicam on prostate cancer cells: development of a new controlled release system. Int J Pharm. 2010;387(1-2):223-29. doi: 10.1016/j.ijpharm.2009.11.036.
  18. Patel M.M., Amin A.F. Formulation and development of release modulated colon targeted system of meloxicam for potential application in the prophylaxis of colorectal cancer. Drug Deliv. 2011;18:281-93. doi: 10.3109/10717544.2010.538447.
  19. Arantes-Rodrigues R., Pinto-Leite R., Ferreira R., et al. Meloxicam in the treatment of in vitro and in vivo models of urinary bladder cancer. Biomed Pharmacother. 2013;67(4):277-84. doi: 10.1016/j.biopha.2013.01.010.
  20. Turck D., Busch U., Heinzel G., Narjes H. Clinical pharma-cokinetics of meloxicam. Eur J Rheumatol Inflamm. 1995;15:22-34.
  21. Distel M., Bluhmki E. Global analysis of safety of meloxicam, a new enolic acid derived nonsteroidal anti-inflammatory agent. Rheumatol Eur. 1995;24(Suppl. 3):39. Doi: 10.1093/ rheumatology/35.suppl_1.68.
  22. Reginster J.Y, Distel M., Bluhmki E. A doubleblind, three-week study to compare the efficacy and safety of meloxicam 7.5 mg and meloxicam 15 mg in patients with rheumatoid arthritis. Br J Rheumatol. 1996;35(Suppl. 1):17-21. doi: 10.1093/rheumatology/35.suppl_1.17.
  23. Pan J.E., Xiong F.L., Chen G., et al. Aquaporin-1 expression as an indicator in evaluating the efficacy of meloxicam in the treatment of ankylosing spondylitis: A comparative study. Biomed Pharmacother. 2017;95:1549-55. doi: 10.1016/j.biopha.2017.08.093.
  24. Randall L.O., Selitto J.J. A method for measurement of analgesic activity on inflamed tissue. Arch Int Pharmacodyn Ther. 1957;111:409-19.
  25. Bekker A., Kloepping J.C., Collingwood S. Meloxicam in the management of post-operative pain: Narrative review. Anaesthesiol Clin Pharmacol. 2018;34(4):450-57. Doi: 10.4103/ joacp.JOACP_133_18.
  26. Engelhardt G., Homma D., Schlegel K., et al. Antiinflammatory, analgesic, antipyretic and related properties of meloxicam, a new non-steroidal antiinflammatory agent with favourable gastrointestinal tolerance. Inflamm Res. 1995;44:423-33. doi: 10.1007/BF01757699.
  27. Distel M., Mueller C., Bluhmki E., Fries J. Safety of meloxicam: a global analysis of clinical trials. Br J Rheumatol. 1996;35(Suppl. 1):68-77. doi: 10.1093/rheumatology/35.suppl_1.68.
  28. Barner A. Review of clinical trials and benefit/risk ratio of meloxicam. Scand J Rheumatol. 1996;102(Suppl.):29-37. doi: 10.3109/03009749609097228.
  29. Dequeker J., Hawkey C., Kahan A., et al. Improvement in gastrointestinal tolerability of the selective cyclooxygenase (COX)-2 inhibitor, meloxicam, compared with piroxicam: Results of the safety and efficacy large-scale evaluation of COX-inhibiting therapies (SELECT) trial in osteoarthritis. Br J Rheumatol. 1998;37:946-51. doi: 10.1093/rheumatology/37.9.946.
  30. Hawkey C, Kahan A., Steinbruck K., et al. Gastrointestinal tolerability of meloxicam compared to diclofenac in osteoarthritis patients. Br J Rheumatol. 1998;37:937-45. Doi: 10.1093/ rheumatology/37.9.937.
  31. Singh G, Lanes S., Triadafilapoulos G. Risk of serios upper gastrointestinal and cardiovascular thromboembolic complications with meloxicam. Am J Med. 2004;117(2):100-6. Doi: 10.1016/j. amjmed.2004.03.012.
  32. Degner F, Sigmund R., Zeidler H. Efficacy and tolerability of meloxicam in an observational, controlled cohort study in patients with rheumatic disease. Clin Ther. 2000;22(4):400-10. doi: 10.1016/S0149-2918(00)89009-8.
  33. Yocum D, Fleischmann R., Dalgin P, et al. Safety and efficacy of meloxicam in the treatment of osteoarthritis: a 12-week, double-blind, multiple-dose, placebo-controlled trial. The Meloxicam Osteoarthritis Investigators. Arch Intern Med. 2000;160(19):2947-54. Doi: 10.1001/ archinte.160.19.2947.
  34. Zeidler H., Kaltwasser J.P, Leonard J.P, et al. Prescription and tolerability of meloxicam in day-to-day practice: postmarketing observational cohort study of 13,307 patients in Germany. J Clin Rheumatol. 2002;8(6):305-15. doi: 10.1097/00124743-200212000-00005.
  35. Pan J.E., Xiong F.L., Chen G., et al. Aquaporin-1 expression as an indicator in evaluating the efficacy of meloxicam in the treatment of ankylosing spondylitis: A comparative study. Biomed Pharmacother. 2017;95:1549-55. doi: 10.1016/j.biopha.2017.08.093.
  36. Kartha S., Weisshaar C.L., Philips B.H., Winkelstei-na B.A. Pre-treatment with meloxicam prevents the spinal inflammation and oxidative stress in DRG neurons that accompany painful cervical radiculopathy. Neuroscience. 2018;388:393-404. doi: 10.1016/j.neuroscience.2018.07.054.
  37. Nekoofar M.H., Sadeghipanah M., Dehpour A.R. Evaluation of meloxicam (A cox-2 inhibitor) for management of postoperative endodontic pain: a double-blind placebo-controlled study. J Endod. 2003;29(10):634-37. doi: 10.1097/00004770-200310000-00005.
  38. Aoki T., Yamaguchi H., Naito H., et al. Premedication with cyclooxygenase-2 inhibitor meloxicam reduced postoperative pain in patients after oral surgery. Int J Oral Maxillofac Surg. 2006;35(7):613-17. Doi: 10.1016/j. ijom.2006.01.026.
  39. Calvo A.M., Sakai V.T., Giglio F.PM. et al. Analgesic and anti-inflammatory dose-response relationship of 7.5 and 15 mg meloxicam after lower third molar removal: a double-blind, randomized, crossover study. Int J Oral Maxillofac Surg. 2007;36(1):26-31. doi: 10.1016/j.ijom.2006.09.006.
  40. Najafi H.Z., Oshagh M., Salehi P, et al. Comparison of the effects of preemptive acetaminophen, ibuprofen, and meloxicam on pain after separator placement: a randomized clinical trial. Prog Orthod. 2015;16:34. doi: 10.1186/s40510-015-0104-y.
  41. Orozco-Solis M., Garcfa-Avalos Y, Pichardo-Ramfrez C., et al. Single dose of diclofenac or meloxicam for control of pain, facial swelling, and trismus in oral surgery. Med Oral Patol Oral Cir Bucal. 2016;21(1):e127-34. Doi: 10.4317/ medoral.20925.
  42. Shao Y, Zhao X., Zhai Y, et al. Comparison of analgesic effect, knee joint function recovery, and safety profiles between pre-operative and postoperative administrations of meloxicam in knee osteoarthritis patients who underwent total knee arthroplasty. Ir J Med Sci. 2020;189(2):535-42. doi: 10.1007/s11845-019-02128-y.
  43. Yuan Y, Cui D., Zhang Y Preemptive meloxicam achieves a better effect on postoperative pain control and similar tolerance compared with postoperative meloxicam in patients receiving arthroscopic knee surgery. Inflammopharmacol. 2019;27(6):1091-100. doi: 10.1007/s10787-019-00614-4.
  44. Hou J., Li W., Chen Y, et al. Early preoperative versus postoperative administration of meloxicam in pain control, patient global status improvement, knee function recovery of arthroscopic knee surgery. Med (Baltimore). 2019;98(40):e17133. doi: 10.1097/MD.0000000000017133.
  45. Ren L., Meng L., Yan H., Sun W., Yao D. Preoperative meloxicam versus postoperative meloxicam for pain control, patients' satisfaction and function recovery in hip osteoarthritis patients who receive total hip arthroplasty: a randomized, controlled study. Inflammopharmacol. 2020;28(4):831-38. doi: 10.1007/s10787-020-00718-2.
  46. Chen J., Gao Y Strategies for meloxicam delivery to and across the skin: a review. Drug Deliv. 2016;23(8):3146-56. doi: 10.3109/10717544.2016.1157839.
  47. Ochi M., Kawachi T, Toita E., et al. Development of nanocrystal formulation of meloxicam with improved dissolution and pharmacokinetic behaviors. Int J Pharm. 2014;474:151-56. doi: 10.1016/j.ijpharm.2014.08.022.
  48. Mack R., Freyeer A., Du W. An evaluation of the efficacy and safety of N1539, a novel intravenous formulation of nanocrystal meloxicam, in subjects with moderate to severe pain following hysterectomy (abstract 409). J Pain. 2016;17:S77. doi: 10.1016/j.jpain.2016.01.386.
  49. Christensen S.E., Cooper S.A., Mack R.J., et al. A randomized double-blind controlled trial of intravenous meloxicam in the treatment of pain following dental impaction surgery. J Clin Pharmacol. 2018;58:593-605. Doi: 10.1002/ jcph.1058.
  50. Viscusi E.R., Gan T.J., Bergese S., et al. Intravenous meloxicam for the treatment of moderate to severe acute pain: a pooled analysis of safety and opioid-reducing effects. Reg. Anesth. Pain Med. 2019;44:360-68. doi: 10.1136/rapm-2018-100184.
  51. Rechberger T., Mack R.J., McCallum S.W., et al. Analgesic Efficacy and Safety of Intravenous Meloxicam in Subjects With Moderate-to-Severe Pain After Open Abdominal Hysterectomy: A Phase 2 Randomized Clinical Trial. Anesth Analg. 2019;128(6):1309-18. Doi: 10.1213/ ANE.0000000000003920.
  52. Bekker A., Kloepping C., Collingwood S. Meloxicam in the management of post-operative pain: Narrative review. J Anaesthesiol Clin Pharmacol. 2018;34(4):450-57. doi: 10.4103/joacp. JOACP_133_18.
  53. Sharpe K.P, Berkowitz R., Tyndall W.A., et al. Tolerability, and Effect on Opioid Use of Meloxicam IV Following Orthopedic Surgery. J Pain Res. 2020;13:221-29. doi: 10.2147/JPR.S216219.
  54. Bergese S.D., Melson T.I., Candiotti K.A., et al. A Phase 3, Randomized, Placebo-Controlled Evaluation of the Safety of Intravenous Meloxicam Following Major Surgery. Clin Pharmacol Drug Dev. 2019;8(8):1062-72. doi: 10.1002/cpdd.666.
  55. Roberts H.R., Smartt H.J.M., Greenhough A., et al. Colon tumour cells increase PGE2 by regulating COX-2 and 15-PGDH to promote survival during the microenvironmental stress of glucose deprivation. Carcinogenes. 2011;32(11):1741-47. doi: 10.1093/carcin/bgr210.
  56. Ke J., Yang Y., Che Q., et al. Prostaglandin E2 (PGE2) promotes proliferation and invasion by enhancing SUMO-1 activity via EP4 receptor in endometrial cancer. Tumor Biol. 2016;37(9):12203-11. doi: 10.1007/s13277-016.
  57. Wong R.S.Y Role of Nonsteroidal AntiInflammatory Drugs (NSAIDs) in Cancer Prevention and Cancer Promotion. Adv Pharmacol Sci. 2019;2019:3418975. doi: 10.1155/2019/3418975.
  58. Ellis J.D., Iqbal R., Yoshimatsu K. A new approach for IR spectra matching using normalized local Change. Analyt Chim Acta. 2019;1103:49-57. Doi: W.W16/j.aca.2019.12.055.
  59. h ttps://kemero vo.uteka.ru/product/ ameloteks-216220/
  60. https://www.starbene.it/farmaci/mobic-15-30cpr-div-15mg_031985068
  61. http://www.medicine.bg/lekarstva/movalis
  62. https://kemerovo.uteka.ru/product/movalis-96678/?utm_source=www.poisklekarstv. com&utm_medium=aggregator
  63. Jung-Woo Bae, Mi-Jeong Kim, Choon-Gon Jang, Seok-Yong Lee. Determination of meloxicam in human plasma using a HPLC method with UV detection and its application to a pharmacokinetic study. J Chromatogr B Analyt Technol Biomed Life Sci. 2007;859(1):69-73. Doi: 10.1016/j. jchromb.2007.09.004.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies